The Athena trials: Autologous adipose‐derived regenerative cells for refractory chronic myocardial ischemia with left ventricular dysfunction
- 5 May 2016
- journal article
- research article
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 89 (2), 169-177
- https://doi.org/10.1002/ccd.26601
Abstract
Objective To assess safety and feasibility of autologous adipose‐derived regenerative cells (ADRCs), for treatment of chronic ischemic cardiomyopathy patients. Background Preclinical and early clinical trials suggest ADRCs have excellent potential for ischemic conditions. Methods The Athena program consisted of two parallel, prospective, randomized (2:1, active: placebo), double‐blind trials assessing intramyocardial (IM) ADRC delivery [40‐million, n = 28 (ATHENA) and 80‐million (ATHENA II) cells, n = 3]). Patients with an EF ≥20% but ≤45%, multivessel coronary artery disease (CAD) not amenable to revascularization, inducible ischemia, and symptoms of either angina (CCS II–IV) or heart failure (NYHA Class II–III) on maximal medical therapy were enrolled. All patients underwent fat harvest procedure (≤450 mL adipose), on‐site cell processing (Celution® System, Cytori Therapeutics), electromechanical mapping, and IM delivery of ADRCs or placebo. Results Enrollment was terminated prematurely due to non‐ADRC‐related adverse events and subsequent prolonged enrollment time. Thirty‐one patients (17‐ADRCs, 14‐placebo) mean age 65 ± 8 years, baseline LVEF(%) 31.1 ± 8.7 (ADRC), 31.8 ± 7.7 (placebo) were enrolled. Change in V02 max favored ADRCs (+45.4 ± 222 vs. −9.5 ± 137 mL/min) but there was no difference in left ventricular function or volumes. At 12‐months, heart failure hospitalizations occurred in 2/17 (11.7%) [ADRC] and 3/14 (21.4%) [placebo]. Differences in NYHA and CCS classes favored ADRCs at 12‐months with significant improvement in MLHFQ (−21.6 + 13.9 vs. −5.5 + 23.8, P = 0.038). Conclusions A small volume fat harvest, automated local processing, and IM delivery of autologous ADRCs is feasible with suggestion of benefit in “no option” CAD patients. Although the sample size is limited, the findings support feasibility and scalability for treatment of ischemic cardiomyopathy with ADRCs.Keywords
Funding Information
- Cytori (Athena Trial Program-Grant Number N/A)
This publication has 22 references indexed in Scilit:
- Treatment of refractory angina in patients not suitable for revascularizationNature Reviews Cardiology, 2013
- Cell Therapy for Heart FailureCirculation Research, 2013
- Stem Cell Therapy Is a Promising Tool for Refractory Angina: A Meta-analysis of Randomized Controlled TrialsCanadian Journal of Cardiology, 2013
- Meta-Analysis of Stem Cell Therapy in Chronic Ischemic CardiomyopathyThe American Journal of Cardiology, 2013
- Bone Marrow Stem Cell Treatment for Ischemic Heart Disease in Patients with No Option of Revascularization: A Systematic Review and Meta-AnalysisPLOS ONE, 2013
- Long-term survival in patients with refractory anginaEuropean Heart Journal, 2013
- Patients With Coronary Artery Disease Unsuitable for Revascularization: Definition, General Principles, and a ClassificationCanadian Journal of Cardiology, 2012
- Effect of Transendocardial Delivery of Autologous Bone Marrow Mononuclear Cells on Functional Capacity, Left Ventricular Function, and Perfusion in Chronic Heart FailureJAMA, 2012
- Clinical and research issues regarding chronic advanced coronary artery disease Part II: Trial design, outcomes, and regulatory issuesAmerican Heart Journal, 2008
- Plasticity of human adipose stem cells toward endothelial cells and cardiomyocytesNature Clinical Practice Cardiovascular Medicine, 2006